Listing Category
Description
A phase 3, open-label, randomized study to assess the efficacy and safety of Camizestrant (AZD9833), a next generation. Oral selective estrogen receptor degrader, versus standard endocrine therapy, as adjusted treatment for patients with ER+/HER2- early breast cancer and an intermediate -high or high risk of recurrence who have completed definitive locoregional treatment and have no evidence or disease